Pharma Business - March 8, 2017
BerGenBio intends to apply for listing on Oslo Børs
BerGenBio has entered an agreement with MSD and announces its intention to launch an Initial Public Offering (IPO) and to apply for a listing on Oslo Børs. The agreement with MSD is a collaborative agreement, through a subsidiary, focused on the clinical evaluation of BGB324 with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung […]
Drug Development Pharma - April 25, 2016
BerGenBio presents new data
BerGenBio announces that preclinical data demonstrating that lead compound, BGB324, combined with immune checkpoint inhibitors has the potential to synergistically improve treatment of human cancers, has been presented at the American Association of Cancer Research Annual Meeting (AACR), April 16-20, 2016 in New Orleans, Louisiana. BGB324 is a first-in-class, highly selective, orally bioavailable small molecule […]
Clinical Trials - May 11, 2015
BerGenBio Cancer Drug in US Trial
A multi-center open label Phase 1b trial of BerGenBio AS’s BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway. The study is conducted at the University of Texas MD Anderson Cancer Center, […]
Financing - December 16, 2014
BenGenBio Raises NOK90 Million
BerGenBio AS, a Norwegian biopharmaceutical company focused on developing medications for aggressive drug- resistant cancers, announced that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors. BerGenBio will use the proceeds from the financing to support the development of its pipeline of innovative cancer therapeutics, in particular an enlarged […]
Funding - December 3, 2014
Oslo Cancer Cluster Names Research Grant Winners
Oslo Cancer Cluster recently named three winners in a competition seeking collaborative projects involving immuno-oncology. The three, BerGen Bio, Targovax and Ultimovacs each will receive MNOK 0,4 from Innovation Norway. BerGenBio will use the award to prove that Axl kinase inhibition may provoke an anti-tumor immune response, working with partners from the University of Bergen, Oslo, […]
Funding - September 24, 2014
BerGenBio granted drug discovery award
Oncology biopharmaceutical company BerGenBio has been granted a GBP 1.6 million seeding drug discovery award from the UK’s Wellcome Trust. The money will go to develop novel small molecule inhibitors against BGB002, its proprietary, novel cancer target. BGB002 controls tumour cell malignant features. This gene is up-regulated in several cancer types including the difficult to treat malignancies such as triple-negative-breast cancer. BerGenBio holds […]
